Literature DB >> 17148569

Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes.

Maria Kolak1, Hannele Yki-Järvinen, Katja Kannisto, Mirja Tiikkainen, Anders Hamsten, Per Eriksson, Rachel M Fisher.   

Abstract

OBJECTIVE: The aim of this study was to compare effects of therapeutic doses of rosiglitazone and metformin on expression of 50 genes in human adipose tissue in vivo.
METHODS: Twenty patients with diet-treated type 2 diabetes (13 women, seven men) were randomized to receive either rosiglitazone (n = 9; 8 mg/d) or metformin (n = 11; 2 g/d) for 16 wk. Subcutaneous adipose tissue biopsies were performed before and after treatment. Expression of 50 genes, previously shown to be altered by thiazolidinediones in experimental models, was quantified by real-time PCR and normalized to two housekeeping genes.
RESULTS: Rosiglitazone, but not metformin, treatment increased expression of genes involved in triacylglycerol storage [e.g. stearyl-CoA desaturase (3.2-fold), CD36 (1.8-fold)], structural genes [e.g. alpha-1 type-1 procollagen (1.7-fold) and GLUT4 (1.5-fold)], and decreased expression of inflammation-related genes [e.g. IL-6 (0.6-fold), chemokine (C-C motif) ligand 3 (0.4-fold)], 11beta-hydroxysteroid dehydrogenase 1 (0.6-fold), and resistin (0.3-fold) (all P < 0.05).
CONCLUSIONS: These results suggest that the insulin-sensitizing action of rosiglitazone involves remodeling of human adipose tissue to reduce inflammation and promote lipid storage. Furthermore, we show some important differences between thiazolidinedione action in human adipose tissue and experimental models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17148569     DOI: 10.1210/jc.2006-1465

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

Review 1.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

2.  Role of adipocyte mitochondria in inflammation, lipemia and insulin sensitivity in humans: effects of pioglitazone treatment.

Authors:  X Xie; S Sinha; Z Yi; P R Langlais; M Madan; B P Bowen; W Willis; C Meyer
Journal:  Int J Obes (Lond)       Date:  2017-08-14       Impact factor: 5.095

3.  Genetics of serum resistin: a paradigm of population-specific regulation?

Authors:  C Menzaghi; V Trischitta
Journal:  Diabetologia       Date:  2009-11-01       Impact factor: 10.122

4.  Insulin Signaling Via Progesterone-Regulated Insulin Receptor Substrate 2 is Critical for Human Uterine Decidualization.

Authors:  Alison M Neff; Jie Yu; Robert N Taylor; Indrani C Bagchi; Milan K Bagchi
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

5.  Urtica dioica extract attenuates depressive like behavior and associative memory dysfunction in dexamethasone induced diabetic mice.

Authors:  Sita Sharan Patel; Malairaman Udayabanu
Journal:  Metab Brain Dis       Date:  2014-01-17       Impact factor: 3.584

6.  B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation.

Authors:  Yu Hee Kim; Bong Hyuk Choi; Hyae Gyeong Cheon; Myoung Sool Do
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

7.  Joint contracture is reduced by intra-articular implantation of rosiglitazone-loaded hydrogels in a rabbit model of arthrofibrosis.

Authors:  Diren Arsoy; Christopher G Salib; William H Trousdale; Meagan E Tibbo; Afton K Limberg; Anthony Viste; Eric A Lewallen; Nicolas Reina; Michael J Yaszemski; Daniel J Berry; Andre J van Wijnen; Mark E Morrey; Joaquin Sanchez-Sotelo; Matthew P Abdel
Journal:  J Orthop Res       Date:  2018-07-13       Impact factor: 3.494

8.  Stearoyl-coenzyme A desaturase 1 gene expression increases after pioglitazone treatment and is associated with peroxisomal proliferator-activated receptor-gamma responsiveness.

Authors:  Aiwei Yao-Borengasser; Negah Rassouli; Vijayalakshmi Varma; Angela M Bodles; Neda Rasouli; Resat Unal; Bounleut Phanavanh; Gouri Ranganathan; Robert E McGehee; Philip A Kern
Journal:  J Clin Endocrinol Metab       Date:  2008-08-12       Impact factor: 5.958

9.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.

Authors:  Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

10.  Enhanced metabolic flexibility associated with elevated adiponectin levels.

Authors:  Ingrid Wernstedt Asterholm; Philipp E Scherer
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.